{
    "clinical_study": {
        "@rank": "131219", 
        "acronym": "BMI>50", 
        "arm_group": [
            {
                "arm_group_label": "Distal gastrojejunal bypass", 
                "arm_group_type": "Experimental", 
                "description": "RYGB with 200 cm BP limb and 150 cm common limb"
            }, 
            {
                "arm_group_label": "RYGB", 
                "arm_group_type": "Active Comparator", 
                "description": "RYGB with 60 cm BP limb and 150 cm alimentary limb"
            }
        ], 
        "brief_summary": {
            "textblock": "Surgical bypassing of a longer section of the small bowel (when doing a gastric bypass\n      operation) gives better results on body weight in the superobese. We do not yet know whether\n      it is beneficial to exclude more of the proximal small bowel or more of the distal. Side\n      effects of bypassing can also be different.\n\n      Study aims at clarifying possible differences in effects and side-effects of these two\n      surgical-technical variations."
        }, 
        "brief_title": "Effects of Long Biliopancreatic Limb Versus Long Alimentary Limb in Superobesity, a Randomized Study", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Super Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "Randomisation in the OR between long biliopancreatic limb and long alimentary limb. GAstric\n      component identical.\n\n      Perioperative biopsies to assess mucosal properties at the gastrojejunostomy and the\n      enteroanastomosis. Repeat biopsies (gastroscopy) at one year to identify changes in the\n      mucosa at the Gastroenteroanastomosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI > 50\n\n        Exclusion Criteria:\n\n          -  Psychiatric disease\n\n          -  Inflammatory bowel disease\n\n          -  inability to understand Swedish"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033577", 
            "org_study_id": "NCT01514799"
        }, 
        "intervention": [
            {
                "arm_group_label": "Distal gastrojejunal bypass", 
                "description": "RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications", 
                "intervention_name": "Distal gastrojejunal bypass", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "RYGB", 
                "description": "RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on", 
                "intervention_name": "RYGB", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "bjnergard@me.com", 
                "last_name": "Bent Johnny Nergaard, MD", 
                "phone": "+4792861730"
            }, 
            "contact_backup": {
                "last_name": "Jan Hedenbro"
            }, 
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden"
                }, 
                "name": "Aleris Obesity"
            }, 
            "investigator": {
                "last_name": "Bent Johnny Nergaard, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Long Biliopancreatic Limb vs Long Alimentary Limb in Superobesity", 
        "other_outcome": {
            "description": "Time to discharge, leaks, bleeding", 
            "measure": "Short-term complications", 
            "safety_issue": "Yes", 
            "time_frame": "0-30 days postoperatively"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "SWEDEN: Lund University IKVL Clinical studies monitoring, c/o Prof R Andersson", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Body weight reduction is currently the best substitute endpoint to correlate with the hard endpopints such as death, comorbidities etc.", 
            "measure": "Body weight reduction", 
            "safety_issue": "No", 
            "time_frame": "2 years from end of inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033577"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Aleris Obesity", 
            "investigator_full_name": "Jan Hedenbro", 
            "investigator_title": "Senior scientist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "We employ SF-36, Op-9, GSRS, TFEQ scales", 
            "measure": "Patient assessed quality of life", 
            "safety_issue": "Yes", 
            "time_frame": "2 years from end of inclusion"
        }, 
        "source": "Aleris Obesity", 
        "sponsors": {
            "collaborator": {
                "agency": "Lund University Diabetes Centre, Malm\u00f6 Sweden", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Aleris Obesity", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}